News and Trends 31 Mar 2023 Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China Ablaze Pharmaceuticals, a biotech company focused on developing targeted radiotherapy (TRT) to benefit cancer patients in China, is developing plans for a first-in-class novel peptide drug candidate against GPC3. The proprietary GPC3-targeting peptide is being licensed from RayzeBio. Upon in-license of product candidates by Ablaze from RayzeBio, Ablaze will be responsible for clinical development and […] March 31, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Mar 2023 67% five-year survival rate in glioblastoma therapy, according to CANbridge Pharmaceuticals study CANbridge Pharmaceuticals Inc. has announced that its therapy for glioblastoma has shown a 67% survival rate at five years, three years after the clinical trials ended. Four out of nine of the patients with newly diagnosed glioblastoma multiforme (GBM) who were part of the clinical study were reported to be alive three years after the […] March 17, 2023 - 3 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 17 Mar 2023 Likang gets trial ok for China’s first personalized cancer vaccine Likang Life Sciences has received implied approval for the clinical trial of its personalized neoantigen-targeted vaccine for advanced solid tumors, LK101 injection. This is the first personalized neoantigen vaccine and mRNA editing product approved by China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to enter the clinical stage. Likang submitted […] March 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2023 Could changing mRNA provide a new target for Alzheimer’s disease? Reducing the methylation of a key messenger RNA can promote migration of macrophages into the brain and ameliorate symptoms of Alzheimer’s disease in a mouse model. This is according to a new study in the open access journal PLOS Biology by Rui Zhang of Air Force Medical University in Xian, Shaanxi, China. The results highlight […] March 8, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Mar 2023 Porton and DanausGT look to boost development of gene and cell therapy Porton Advanced Solutions Ltd. and DanausGT Biotechnology Co., Ltd. have announced a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics. As an end-to-end gene and cell therapy service provider, Porton Advanced CDMO offers solutions covering plasmids, cell therapy, gene therapy, oncolytic viruses, mRNA therapy, and bacterial therapy. DanausGT […] March 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2023 Biocytogen launches nanobody therapeutics project for 100 targets Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has launched the “Nano 100 Project,” which aims to develop fully human nanobody drugs for more than 100 targets. The project combines Biocytogen’s proprietary fully human nanobody mouse, RenNano, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale. Compared […] February 21, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2023 Report: China leads the way with phase 1 studies Novotech, an Asia Pacific biotech CRO, has published a new global report on phase 1 trial activity including current metrics on fast growth regions and therapeutic areas. The data analysis found that Asia Pacific has been the fastest-growing region for phase 1 clinical trials in the last 10 years, reaching a share of 58% in […] February 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jan 2023 HKUMed uncovers T cell exhaustion factor driving cancer immunotherapy resistance A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has identified an unexpected driver of cancer immunotherapy resistance: the harmful effect of chronic Type I Interferon signaling on tumor-killing CD8+ T cells. The findings provided new insights into the development of exhausted CD8+ T cells, which no longer effectively […] January 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Lifesciences and biotech in 2023 A Q&A with Bill Coyle, principal, ZS. ZS is a management consulting and technology firm focused on transforming global healthcare. In some ways, 2022 could be seen as a challenging year—at least financially—in biotech. Do you see those trends continuing? Although we see overall sentiments to invest in biotech turning positive in 2023 after a […] January 11, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 Cartherics granted first patent in China Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, has been granted a Chinese patent, “Genetically modified cells and uses thereof.” The patent provides a proprietary position for multiple development candidates in Cartherics’ pipeline. Specifically, it covers Cartherics’ chimeric antigen receptor (CAR) targeting tumor-associated glycoprotein-72 (TAG-72), along with T […] January 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2023 Legend Biotech new drug application approved in China Legend Biotech Corporation has announced that China’s National Medical Products Administration (NMPA) has formally accepted its new drug application (NDA) for ciltacabtagene autoleucel (cilta-cel). This submission is based on data from the confirmatory phase 2 clinical study CARTIFAN-1, conducted in China, which evaluated the efficacy and safety of cilta-cel in adult patients with relapsed or […] January 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2022 Jacobio’s cancer treatment given breakthrough therapy designations by China CDE Jacobio Pharma’s in-house KRAS G12C inhibitor JAB-21822 has been granted breakthrough therapy designations in China. The designations are for the second line and above treatment of advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRAS G12C mutation. The designations were granted by the Center for Drug Evaluation (CDE) of the National Medical Products […] December 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email